Research News

Latest Advances in Lung Cancer Research

Explore our curated selection of the latest breakthroughs in lung cancer research.

Clear Filter
  • February 25, 2022

    New Cancer Tool Gets Breakthrough Status

    FDA grants breakthrough designation to FoundationOne Tracker, an assay for detecting MRD in cancer, aiding treatment decisions and relapse monitoring.

    MD+DI: Medical Device and Diagnostic Industry

  • February 19, 2022

    Lung Cancer Screening Expanded by Medicare

    Medicare expands LDCT lung cancer screening eligibility, lowering age to 50 and pack-year history to 20, streamlining processes to improve early detection.

    Fierce Healthcare

  • February 18, 2022

    Profile Lung Cancer in Never Smokers

    Lung cancer in never smokers presents unique molecular traits and lower mutation burdens, necessitating distinct treatment strategies and revised screening criteria.


  • February 8, 2022

    Lung Cancer Drives Overall Decline in Cancer Deaths

    American Cancer Society report shows lung cancer deaths decline, boosting overall cancer survival despite persistent disparities and need for better screening.

    U.S. News

    Lung Cancer Info
  • January 22, 2022

    Breakthrough Therapy for EGFR NSCLC

    FDA grants breakthrough designation to CLN-081, a targeted therapy for NSCLC with EGFR exon 20 mutations, showing promise in ongoing clinical trials.


  • January 22, 2022

    Decreased Lung Cancer Deaths with Early Detection

    Mount Sinai study shows earlier lung cancer diagnosis via CT screening significantly reduces deaths, underscoring the need for widespread screening adherence.

    News Medical Life Sciences

  • January 13, 2022

    Lung Cancer in Never Smokers

    Most never-smokers’ lung tumors have targetable mutations matched to FDA-approved drugs, unlike smokers’ tumors. Testing is critical.


    Targeted Therapy Treatment
  • January 12, 2022

    What Is Exon Insertion in NSCLC?

    Rare EGFR exon insertions in lung cancer allow targeted therapies, but resistance develops; new drugs help.

    Verywell Health

  • January 11, 2022

    Imfinzi plus chemotherapy tripled survival


    Imfinzi plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial for patients with extensive-stage SCLC.


Get the latest lung cancer research news directly in your inbox.

Learn more about:

  • the latest science in lung cancer
  • stories about living with lung cancer
  • how LCFA is working to fund more lung cancer research grants

LCFA prioritizes providing reliable information about new diagnostics, treatments, and prevention strategies, including exciting FDA-approved personalized therapies based on individual tumor biomarkers.